Medicenna Therapeutics (MDNAF) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing next-generation cytokine-based immunotherapies for cancer and central nervous system disorders. The company applies protein-engineering approaches to create engineered cytokine therapeutics designed to enhance anti-tumor activity while reducing systemic toxicity, aiming to broaden the therapeutic window for immunomodulatory agents.

Medicenna’s pipeline includes proprietary candidates such as MDNA55, an engineered interleukin-4 (IL-4) receptor-targeted fusion protein developed for intratumoral treatment of recurrent glioblastoma and other brain tumors, and MDNA11, a long-acting engineered interleukin-2 (IL-2) “superkine” intended to stimulate anti-tumor immune responses in solid tumors with an improved safety profile. The company also advances additional discovery- and preclinical-stage programs that leverage its cytokine-engineering platform to address unmet needs in oncology and neuro-oncology.

Medicenna conducts clinical development programs and collaborates with academic and industry partners to advance its candidates through clinical trials. Headquartered in Canada, the company operates in the clinical research environment with study activity in North America and internationally. Its strategy emphasizes targeted delivery and molecular redesign of cytokines to improve efficacy and tolerability for patients with difficult-to-treat cancers and central nervous system malignancies.

Key Stats

• Today's Range: $0.25 to $0.26
• 50-Day Range: $0.25 to $0.49
• 52-Week Range: $0.25 to $1.43
• Volume: 11,500 shs
• Average Volume: 80,563 shs
• Market Capitalization: $23.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Medicenna Therapeutics Stock Analysis - MarketRank™

Medicenna Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Medicenna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Medicenna Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Medicenna Therapeutics are expected to grow in the coming year, from ($0.18) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicenna Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicenna Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medicenna Therapeutics has a P/B Ratio of 12.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.13% of the float of Medicenna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Medicenna Therapeutics has a short interest ratio ("days to cover") of 5.16.

Change versus previous month

Short interest in Medicenna Therapeutics has recently decreased by 1.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicenna Therapeutics does not currently pay a dividend.

Dividend Growth

Medicenna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.85% of the stock of Medicenna Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 6/25/2026
• Today: 7/17/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MDNAF
• CIK: 1807983
• Web: www.medicenna.com
• Phone: (416) 648-5555
• Fax: 416-572-7501
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1.37%
• Return on Assets: -0.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.52
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 12.90

Miscellaneous

• Outstanding Shares: 92,300,000
• Free Float: 61,749,000
• Market Cap: $23.80 million
• Optionable: N/A
• Beta: 1.75